Response rates in a key group shrink from 62% to 39% as the company blames a “clerical error”.
ApexOnco Front Page
Recent articles
What similarly acting projects are still unpartnered?
An analysis of OncologyPipeline shows that $144bn has been pledged for ADCs since the start of 2022.
The group reckons big pharma is eyeing KIF18A inhibition, but for now there are just a handful of players.
Despite a growing presence outside cancer, the company wants to stay true to its “DNA”.
Blockade of CCR8 has quietly emerged as a hot oncology target, especially for anti-PD-(L)1 MAb combinations.
Readout of the delayed Galaxies Lung-201 study is due imminently.
A year-end pipeline update reveals Boehringer Ingelheim’s oncology priorities.
